Jon R. Moeller, an insider at Eli Lilly and Co (LLY), purchased 304 shares of the company's stock at a price of $1,021.70 per share, resulting in a total transaction value of $311,000. This transaction occurred on November 16, 2025.
Following this acquisition, Moeller holds a total of 304 shares of Eli Lilly. The company's market capitalization stands at $965.9 billion, with a price-to-earnings (P/E) ratio of 52.46 and earnings per share (EPS) of 20.45. Eli Lilly's dividend yield is currently 58.7%.
Eli Lilly engages in the discovery, development, manufacture, and sale of pharmaceutical products, employing approximately 47,000 full-time staff. Its product portfolio includes treatments for cardiometabolic health, oncology, immunology, and neuroscience. Upcoming earnings reports are expected on April 28, 2026, with an EPS estimate of $7.16 and revenue of $17.1 billion, followed by another report on August 4, 2026, estimating an EPS of $7.86 and revenue of $18.7 billion.
Insider transactions like Moeller's can provide insight into executive confidence in the company's future. However, such activities should be considered alongside broader market analysis and not in isolation.